Genetic editing holds promise to treat incurable diseases, but the most popular method—CRISPR—sometimes does more harm than ...

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

A research team led by scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) has introduced a new ...

PlantArcBio, an Israeli ag-biotech firm, has secured patents in the U.S. and South Korea for its DIPPER platform. This ...

Genetic editing holds promise to treat incurable diseases, but the most popular method — CRISPR — sometimes does more harm than good. A new study from University of California San Diego and Yale ...

Completed patient enrollment within nine months with nearly half enrolled from the U.S.Expect to report Phase 3 topline data ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

DIPPER™ platform accelerates development of drought-tolerant, high-yield, and resilient crops worldwide TEL AVIV, Israel, Sept. 18, 2025 /PRNewswire/ ...

The global cell and gene therapy market is experiencing significant expansion, driven by rising approvals and advancements in ...

The Tel Aviv-based company said the technology enhances the precision and efficiency of tools like CRISPR, accelerating the development of traits such as drought tolerance, yield improvement, and ...